Cadrenal Therapeutics Files Proxy Materials

TL;DR

CADX filed proxy docs, nothing major revealed yet.

AI Summary

Cadrenal Therapeutics, Inc. filed definitive additional materials on June 12, 2024, related to its proxy statement. The filing concerns the company's operations and shareholder matters, as is typical for a DEFA14A filing. No specific financial transactions or significant corporate events are detailed in this particular document excerpt.

Why It Matters

This filing indicates ongoing corporate governance activities and shareholder communication for Cadrenal Therapeutics, Inc., which is standard procedure for publicly traded companies.

Risk Assessment

Risk Level: low — This filing is a routine proxy statement, providing no new material information that would immediately impact risk.

Key Players & Entities

• Cadrenal Therapeutics, Inc. (company) — Registrant
• 0001213900-24-052088.txt (document) — Filing identifier
• 20240612 (date) — Filing date

FAQ

Filing Documents

• ea0206592-05.htm (DEFA14A) — 35KB
• tcadrenal_logo.jpg (GRAPHIC) — 46KB
• tproxy_001.jpg (GRAPHIC) — 1049KB
• tproxy_002.jpg (GRAPHIC) — 839KB
• 0001213900-24-052088.txt ( ) — 2701KB

From the Filing

ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ SCHEDULE 14A ___________________ Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant   Filed by a party other than the Registrant   Check the appropriate box:   Preliminary Proxy Statement   Confidential, for Use of the Commission Only (as permitted by Rule 14a -6 (e)(2))   Definitive Proxy Statement   Definitive Additional Materials   Soliciting Material Pursuant to Section 240.14a -12 CADRENAL THERAPEUTICS, INC. (Name of Registrant as Specified in Its Charter) ______________________________________________________________ (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply):   No fee required.   Fee paid previously with preliminary materials.   Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0 -11 .   SCAN TO VIEW MATERIALS & VOTE CADRENAL THERAPEUTICS, INC. C/O TRANSFER ONLINE 512 SE SALMON STREET PORTLAND, OR 97214 VOTE BY INTERNET - www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information. Vote by 11:59 P.M. ET on 7/28/2024. Have your proxy card in hand when you access the web site at www.proxyvote.com and follow the instructions to obtain your records and to create an electronic voting instruction form. VOTE BY PHONE - 1-800-690-6903 Use any touch-tone telephone to transmit your voting instructions. Vote by 11:59 P.M. ET on 7/28/2024. Have your proxy card in hand when you call and then follow the instructions. VOTE BY MAIL Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. The Board of Directors recommends you vote FOR the following: For Withhold For All All All Except 1. Election of Directors Directors 01 John Murphy 02 Robert Lisicki The Board of Directors recommends you vote FOR proposals 2 through 6. For Against Abstain 2 To ratify the appointment of WithumSmith+Brown, PC as our independent registered public accounting firm for our fiscal year ending on December 31, 2024. 3 Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to, at the discretion of the Board, effect a reverse stock split with respect to the Company’s issued and outstanding Common Stock, at a ratio of 1-for-2 to 1-for-20 (the “Range”), with the ratio within such Range to be determined at the discretion of the Board and included in a public announcement. 4 Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to, at the discretion of the Board, increase the number of authorized shares of Common Stock that the Company will have authority to grant from 75,000,000 to 125,000,000. To withhold authority to vote for any individual nominee(s), mark “For All Except” and write the number(s) of the nominee(s) on the line below. For Against Abstain 5 Approval of an amendment to our 2022 Successor Equity Incentive Plan (the “2022 Plan”) to increase the number of shares of Common Stock that will be available for awards under the 2022 Plan by 2,000,000 shares to 4,604,550 shares and to amend the evergreen provision such that the number of reserved shares of Common Stock available for issuance each year will be equal to 20% of: (i) the shares of Common Stock outstanding at December 31 plus; (ii) the shares of Common Stock issuable upon exercise of warrants and pre-funded warrants outstanding at December 31. 6 Approval of an adjournment of the 2024 Annual Meeting of Stockholders to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event there are not sufficient votes in favor Proposal 3, Proposal 4 and/or Proposal 5. NOTE: Such other business as may properly come before the meeting or any adjournment thereof. Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If it is a corporation or partnership, please sign in full corporate or partnership name, by authorized officer. Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date 0000648623_1 R1.0.0.6   Important Notice Regarding the Availa

View Full Filing

View this DEFA14A filing on SEC EDGAR